General Information of Drug (ID: DMOR8SY)

Drug Name
CNT0-1959 Drug Info
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMOR8SY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Interleukin-23 (IL23)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ustekinumab DMHTYK3 Plaque psoriasis EA90.0 Approved [3]
Tildrakizumab DMLW9HG Plaque psoriasis EA90.0 Approved [4]
CNTO-1959 DMPC2QY Plaque psoriasis EA90.0 Approved [2]
Risankizumab DMM32GT Plaque psoriasis EA90.0 Approved [5]
BI 655066 DMBH4FL Chronic plaque psoriasis EA90.0 Phase 3 [6]
MK-3222 DMQBF7O Hairy cell leukaemia 2A82.2 Phase 3 [7]
Brazikumab DM4NWPE Crohn disease DD70 Phase 3 [8]
ABP 654 DM0GXWT Plaque psoriasis EA90.0 Phase 3 [9]
mRNA-2752 DMUKBI2 Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
AMG-139 DMEHOVF Crohn disease DD70 Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-23 (IL23) TTC1GLB IL23A_HUMAN Not Available [2]

References

1 Anti-Interleukin-23 Monoclonal Antibody Guselkumab Shows Significant Efficacy in Treatment of Moderate to Severe Plaque Psoriasis. Janssen Research & Development, LLC (Janssen). Mar 24, 2014.
2 Interleukin-23 in the pathogenesis and treatment of psoriasis. Skin Therapy Lett. 2015 Mar-Apr;20(2):1-4.
3 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
4 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
6 Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015 Jul;136(1):116-124.e7.
7 Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9.
8 Blockade of IL-23: What is in the Pipeline? J Crohns Colitis. 2022 May 11;16(Supplement_2):ii64-ii72.
9 Clinical pipeline report, company report or official report of Amgen
10 Clinical pipeline report, company report or official report of Moderna Therapeutics.
11 Preclinical development of AMG 139, a human antibody specifically targeting IL-23. Br J Pharmacol. 2015 Jan;172(1):159-72.